Aclaris Therapeutics Inc. (NASDAQ: ACRS) announced positive interim results from its Phase 1a trial of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE